Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Castle Biosciences Inc.
< Previous
1
2
Next >
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
October 29, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Participate in Upcoming Investor Conferences
October 28, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
October 20, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
October 16, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
October 14, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
October 11, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
October 09, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
October 02, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
September 27, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
September 23, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
September 16, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
September 11, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
September 05, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Participate in Upcoming Investor Conferences
August 28, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Reports Second Quarter 2024 Results
August 05, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
July 30, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
July 22, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
July 15, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Honored with Top Workplaces Awards
July 11, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
June 24, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
June 14, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
May 30, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
May 29, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
May 15, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
May 14, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
May 10, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
May 08, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
May 03, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Reports First Quarter 2024 Results
May 02, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.